NAUT Nautilus Biotechnology, Inc.: Indikator likuiditas cepet

The price chart for Nautilus Biotechnology (NAUT) allows for an assessment of the effectiveness of its competition for market share in proteomics, where the company's advantage is driven by patented chips for low-cost DNA analysis, and the metric stands at 9.21. The business is optimizing costs by outsourcing the production of consumables to contractors and utilizing cloud computing. Its environmental strategy is based on the safe disposal of electronics and standard energy conservation.

By implementing an innovative proteomic analysis platform for the pharmaceutical industry, Nautilus Biotechnology (NAUT) is in an active growth stage where access to working capital is critical. This short-term solvency assessment, excluding inventories, measures the company's ability to cover current liabilities solely through cash and accounts receivable, ignoring low-liquidity assets to determine the actual margin of financial strength.